Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6098464 | 0.87 | TLR8 (0.45) | TLR7TLR8 | |
| SCHEMBL4793756 | 0.87 | SMN1; SMN2 (0.47) | TLR7TLR8 | |
| SCHEMBL6094271 | 0.85 | PIM1 (0.40) | TLR7TLR8 | |
| SCHEMBL4875215 | 0.84 | TLR7 (0.39) | TLR7TLR8 | |
| SCHEMBL4792366 | 0.84 | HPGD (0.39) | TLR7TLR8 | |
| SCHEMBL4794750 | 0.84 | HPGD (0.39) | TLR7TLR8 | |
| SCHEMBL4792078 | 0.84 | HPGD (0.39) | TLR7TLR8 | |
| SCHEMBL4792944 | 0.83 | HPGD (0.40) | TLR7TLR8 | |
| SCHEMBL4791339 | 0.83 | TLR7 (0.36) | TLR7TLR8 | |
| SCHEMBL4790904 | 0.82 | TLR7 (0.36) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098221-B2 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-08-29 | — | — | US | disclosed |
| US-20050282854-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-12-22 | — | — | US | disclosed |
| US-6969722-B2 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-11-29 | — | — | US | disclosed |
| US-6903113-B2 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-07 | — | — | US | disclosed |
| US-6878719-B2 | Sulfonamido substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040186128-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-23 | — | — | US | disclosed |
| US-20040157879-A1 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-08-12 | — | — | US | disclosed |
| US-20040147533-A1 | Sulfonamido substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-29 | — | — | US | disclosed |
| US-6720334-B2 | IMMUNE RESPONSE MODIFIERS; CYTOKINE BIOSYNTHESIS; VIRAL AND NEOPLASTIC DISEASES; 1-(4-(4-AMINO-6,7-DIMETHYL-1H-IMIDAZO (4,5-C)PYRIDIN-1-YL)BUTYL)-3-PHENYLUREA. | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-13 | — | — | US | disclosed |
| US-6720333-B2 | IMMUNE RESPONSE MODIFIERS; CYTOKINE BIOSYNTHESIS; VIRAL AND NEOPLASTIC DISEASES; N-(4-(4-AMINO-6,7-DIMETHYL-1H-IMIDAZO (4,5-C)PYRIDIN-1-YL)BUTYL)BENZAMIDE | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-13 | — | — | US | disclosed |
| US-6696465-B2 | INDUCING BIOSYNTHESIS OF CYTOKINES; VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-02-24 | — | — | US | disclosed |
| US-20040019076-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-29 | — | — | US | disclosed |
| US-20030195209-A1 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-16 | — | — | US | disclosed |
| US-20030186949-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-02 | — | — | US | disclosed |
| US-20030176458-A1 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-09-18 | — | — | US | disclosed |
| US-20030162806-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-28 | — | — | US | disclosed |
| US-6545017-B1 | Inducing cytokine biosynthesis; treating a viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-6545016-B1 | Inducing cytokine biosynthesis; treating a viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-6525064-B1 | Immune response modifiers; can induce the biosynthesis of various cytokines; | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-20020107262-A1 | SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2002-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186128-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | TLR7 75/4885TLR8 55/4885 |
| US-20030176458-A1 | Urea substituted imidazopyridines | EIF2AK2, UMPS, IRF3 | TLR7 269/4885TLR8 341/4885 |
| US-20030195209-A1 | Urea substituted imidazopyridines | EIF2AK2, UMPS, IRF3 | TLR7 269/4885TLR8 341/4885 |
| US-20050282854-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | TLR7 75/4885TLR8 55/4885 |
| US-20040157879-A1 | Urea substituted imidazopyridines | EIF2AK2, UMPS, IRF3 | TLR7 269/4885TLR8 341/4885 |
| US-20020107262-A1 | SUBSTITUTED IMIDAZOPYRIDINES | IRF3, IFNG, EIF2AK2 | TLR7 61/4885TLR8 70/4885 |
| US-20040147533-A1 | Sulfonamido substituted imidazopyridines | IRF3, EIF2AK2, MYD88 | TLR7 52/4885TLR8 62/4885 |
| US-20030162806-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | TLR7 75/4885TLR8 55/4885 |
| US-20040019076-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | IRF3, EIF2AK2, MYD88 | TLR7 52/4885TLR8 62/4885 |
| US-20030186949-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | TLR7 75/4885TLR8 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.